










<https://doi.org/10.1038/s41467-021-25901-z>

OPEN

Publisher Correction: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer

Carla L. Alves , Sidse Ehmsen , Mikkel G. Terp, Neil Portman, Martina Tuttolomondo ,
Odd L. Gammelgaard , Monique F. Hundebøl, Kamila Kaminska, Lene E. Johansen, Martin Bak ,
Gabiella Honeth, Ana Bosch, Elgene Lim  & Henrik J. Ditzel 

Correction to: *Nature Communications* <https://doi.org/10.1038/s41467-021-25422-9>, published online 25 August 2021.

The original HTML version of this Article was updated shortly after publication because the previous HTML version linked to an incorrect Transparent Peer Review file.

Published online: 16 September 2021

Additional information

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41467-021-25901-z>.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2021